Company Overview
Hyperfine, Inc. operates within the healthcare sector specifically focusing on the medical devices industry, where it engages in the production, supply, service, and commercialization of magnetic resonance imaging products. Its primary offering, the Swoop Portable MR Imaging System, is engineered to generate images at a lower magnetic field strength than conventional MRI scanners, distinguishing its operational model from standard imaging equipment providers. The company maintains a market capitalization of $108.73M and reports a trailing twelve-month revenue of $13.56M while employing a workforce of 102 individuals. These valuation and revenue figures indicate that Hyperfine, Inc. functions as a small-cap entity with a revenue base that is relatively modest compared to large-cap medical device conglomerates, suggesting a niche positioning in the portable imaging market rather than broad-scale dominance.
Financial Health
The company reported revenue of $13.56M, net income of -$35,574,000, and EBITDA of -$35,995,000 for the trailing twelve months. The significant gap between the $13.56M revenue and the -$35,574,000 net income reveals a cost structure where operating expenses and losses heavily outweigh gross profits, resulting in a net loss more than double the revenue figure. Free cash flow stands at -$17,207,124, which indicates that the company is currently consuming cash rather than generating it, implying limited immediate financial flexibility to fund operations without external capital. Margin analysis shows a gross margin of 49.8%, which suggests efficient production costs relative to sales, but this is counterbalanced by an operating margin of -144.9% and a profit margin of -262.3%, indicating severe underperformance in covering overhead and generating net profit. On the balance sheet, the company holds $35.09M in cash against $314,000 in debt, supported by a debt-to-equity ratio of 0.77. While the high cash position relative to debt suggests a conservative liquidity stance regarding interest obligations, the negative equity implications of the losses complicate the overall leverage picture. The current ratio is 4.34, which indicates a strong ability to meet short-term liabilities with short-term assets, providing a robust buffer for immediate operational needs. Return on Equity is -79.0% and return on assets is -40.6%, metrics that reveal management is currently destroying shareholder value and failing to generate returns on the capital employed in the business.
Valuation Assessment
The valuation metrics present a complex picture given the lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -3.36. The difference between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in future earnings recovery, though the negative forward P/E technically signals that future earnings are still expected to be negative or that the valuation model relies on projected cash flows rather than earnings. The price-to-book ratio is 2.63, indicating that the market values the company at a premium of 163% over its book value, which can occur in growth-oriented or distressed sectors where intangible assets or future potential are priced in rather than current earnings. Alternative valuation metrics such as the price-to-sales ratio of 8.02 and an EV/EBITDA of -2.06 suggest that investors are valuing the firm based on its revenue generation capability despite its current lack of profitability, as EV/EBITDA remains negative. The stock has traded between a 52-week low of $0.53 and a 52-week high of $2.22, and without a specific current share price provided in the facts, the position relative to this range cannot be precisely calculated, but the range itself demonstrates significant volatility typical of small-cap biotech or device stocks. The beta value is 1.11, which means the stock's price volatility is 11% higher than the broader market, reflecting higher risk and potential for larger swings in price compared to large-cap healthcare indices.
Growth & Income
Revenue growth year-over-year is recorded at 128.0%, while earnings growth is listed as N/A due to the company's ongoing losses. The absence of positive earnings growth compared to the explosive revenue expansion implies that the company is prioritizing top-line scaling and market penetration over immediate profitability, a common strategy in the early stages of commercializing new medical device technologies. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute cash to shareholders and instead reinvests all available capital, including cash flow, back into operations and product development. This reinvestment strategy aligns with the revenue growth figure, suggesting that the company is leveraging its $35.09M cash reserve to fuel expansion rather than returning it to investors. The overall growth and income profile is characterized by high revenue expansion coupled with zero dividend income and negative earnings, presenting a high-risk, high-potential-reward scenario typical of early-stage medical technology firms.